Oxford trial moves into next phase
nLONDON: Days after reports suggested that a promising coronavirus disease (Covid-19) vaccine being developed by the Oxford Vaccine Group showed limited success on monkeys but could fail to prevent transmission of the virus, the developers of the vaccine at the University of Oxford described their efforts as progressing “very well”, moving to the next phase after completing 1,000 immunisations by its candidate-vaccine on healthy human adults.
The human trials were first initiated in April. The next phase, the second in the typical three phases of trials that a vaccine goes through, involves enrolling up to 10,260 adults and children to assess the immune response to the vaccine in people of different ages and assess if there is a variation.
The Oxford study is merging Phases II and III for a speedier development. Phase III involves assessing how the vaccine works in a large number of people over the age of 18, and how well it prevents people from becoming infected and